Research desk · CLCS · OTC
CLCS Stock
SEC financials, peer compare, and chart. Scores open the matching desk. Research only — not advice.
Cell Source, Inc. · Pharmaceutical Preparations
Cell Source, Inc. financial statements, chart, and peer compare from SEC filings.
Cell Source, Inc. (CLCS) discovers, develops, or markets pharmaceutical products.
- Market cap
- $26.17M
- P/E
- -3.42
- Op. margin
- 2,896.16%
- Profit margin
- 3,882.17%
- FCF margin
- 1,991.33%
- ROE
- 29.55%
Related Health Care stocks: SMMT stock financials · INBX stock financials · ANIX stock financials · COGT stock financials · PVLA stock financials
CLCS financial statements
Each Compare name is its own block of years. Filing lines are SEC reports; P/E and price sit on that name’s TTM column only.
CLCS stock peer compare
Each bar is that name’s percent vs its last TTM, on one zero line. Zero is unchanged. This ticker is the black bar.
Focus chart
Zero is unchanged vs last TTM. Every name is a percent for the metric you pick.
CLCS stock peer headlines
Yahoo Finance RSS for CLCS and the names in Compare.
| Ticker | Date | Headline |
|---|---|---|
| Loading headlines… | ||
CLCS stock price chart
Overlays follow the Compare table.
CLCS stock — research snapshot
Screen strengths and watchouts for CLCS stock from the latest Misprise snapshot.
Strengths
- ROE 29.6% — efficient equity returns.
- Operating margin 2,896.2% — solid operating leverage.
- Profit margin 3,882.2% — durable bottom-line quality.
- FCF margin 1,991.3% — cash conversion looks healthy.
- Debt/equity 0.00 — leverage looks manageable.
Watchouts
- ROA -2,034.9% — muted asset returns.
- EPS CAGR negative — earnings trajectory is soft.
- Current ratio 0.03 — near-term liquidity is tight.
- Rev CAGR 5Y —
- Rev CAGR 3Y —
- EPS CAGR 5Y —
- EPS CAGR 3Y -9.7%
- FCF CAGR 5Y 0.7%
- FCF CAGR 3Y -7.4%
CLCS stock FAQs
Short answers for CLCS stock — statements, sector, and how this page is meant to be used.
What is CLCS stock?
Cell Source, Inc. (CLCS) discovers, develops, or markets pharmaceutical products. CLCS stock sits in Health Care (Pharmaceutical Preparations), listed on OTC.
Where can I find Cell Source, Inc. financial statements?
Cell Source, Inc. financial statements — income statement, balance sheet, and cash flow — are on this CLCS stock page, parsed from SEC 10-K and 10-Q filings. Use Annual or Quarterly, then the statement tabs. Research only.
What happened to CLCS stock?
This page is a research snapshot of Cell Source, Inc. (CLCS) from the latest SEC filings in the Misprise database as of TTM. It is not a news feed or a delisting notice. Open the financial statements, chart, and peer compare below, then read the filings. Research only — not financial advice.
Does this page show the CLCS stock price?
The live chart on this CLCS stock page is the same TradingView chart as the screener. Statement tables use SEC filings. Any price or multiple on the TTM column is a market snapshot from the last seed, not a real-time quote. Research only.
What sector is CLCS stock in?
Cell Source, Inc. is classified in Pharmaceutical Preparations, inside the Health Care sector, and trades on OTC. This page is a research snapshot, not a full company profile.
How do I read CLCS financial statements?
Start with this ticker’s block (TTM, then its fiscal years or quarters). Each Compare name is a separate block of its own periods — not mixed by year. A blank is a period we do not have, not a zero. Research only — not a buy or sell.
Where does the CLCS statement data come from?
Income, balance sheet, and cash-flow lines are parsed from SEC company filings (10-K / 10-Q and 20-F). TTM is the last four reported quarters added together, not a separate filing. P/E, forward P/E, price, and market cap are a market quote at last seed — trailing P/E from the quote when available, otherwise last price divided by TTM EPS. They are not 10-K line items and appear on the TTM column only. Research only — not financial advice.
Where can I find the CLCS income statement, balance sheet, and cash flow?
On this CLCS stock page, open Financial statements and use the Income, Balance sheet, and Cash flow tabs. Growth and valuation sit under More. Filing figures are from SEC reports; valuation multiples are the market snapshot described above.
What is the Misprise Score for CLCS stock?
CLCS stock currently scores 1/100 (Watch / incomplete (<60)). Cell Source, Inc. scores weaker or incomplete on durable growth/quality inputs — leverage, coverage, and recent results deserve extra scrutiny. The score is a screen of quality, growth, and balance-sheet inputs — not a price target. Compare it in the Misprise screener; it is not a separate score page.
How is the CLCS comparison winner decided?
Lead and Tie follow the number printed on each factor row, not a blended category score. Growth, quality, score, current ratio, and coverage: the higher figure leads. Value multiples (P/E, PEG, P/B, P/S) and debt ratios: the lower figure leads. Tie appears only when those printed numbers match. The header winner is whoever takes more of those five rows. CAGR uses the 5-year horizon and drops to 3-year only when both names report it. Research only — not a buy or sell.
What is the Anomaly Score on this CLCS page?
Anomaly Score is how unusual a filing pattern is versus this company’s own history and its industry — not the same as Misprise Score. A high anomaly with a weak Misprise Score is often a noisy name. Open the anomaly detector to see the flag. Research only — not financial advice.
What does the green grant dot mean on CLCS stock?
A green circle next to the title means this ticker appears in the Misprise grants calendar with a recent federal award (USASpending / SAM). Tap the dot for date, agency, and amount when available. It is a research flag only — not a buy or sell signal.
Is CLCS stock a buy?
No recommendation either way. This CLCS stock page organizes statements, ratios, and peers so you can do your own work. It is educational only — not advice to buy or sell Cell Source, Inc..